ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Pre-Emptive Treatment Helped Curtail Panitumumab Toxicity

January 30, 2009

Tobacco Council Announces 11 New Grant Awards

January 24, 1975

Editorial: Ambiance Through Exclusion

May 20, 1994

NCI exceeds employment ceilings, must cut personnel in FY 2004, NIH says. Further cuts expected in extramural grant support staff.

January 30, 2004

Brain Tumor Research Needs Stronger Interdisciplinary Collaboration, PRG Says.

November 17, 2000

ACS Elects New Volunteer Leaders

November 19, 2010